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Panus giganteus, a culinary and medicinal mushroom consumed by selected indigenous communities in Malaysia, is currently
being considered for large scale cultivation. This study was undertaken to investigate the hepatoprotective eﬀects of P. giganteus
against thioacetamide- (TAA-) induced liver injury in Sprague-Dawley rats. The rats were injected intraperitoneally with TAA
thrice weekly and were orally administered freeze-dried fruiting bodies of P. giganteus (0.5 or 1 g/kg) daily for two months, while
control rats were given vehicle or P. giganteus only. After 60 days, rats administered with P. giganteus showed lower liver body
weight ratio, restored levels of serum liver biomarkers and oxidative stress parameters comparable to treatment with the standard
drug silymarin. Gross necropsy and histopathological examination further confirmed the hepatoprotective eﬀects of P. giganteus.
This is the first report on hepatoprotective eﬀects of P. giganteus. The present study showed that P. giganteus was able to prevent or
reduce the severity of TAA-induced liver injury.
1. Introduction
The liver plays an important role in the detoxification of
foreign substances, in the secretion of bile for digestion, and
in the metabolic functions of various nutrients including
carbohydrates, proteins, and fats [1]. Hence, chronic liver
injury has serious medical consequences. A common chronic
disease known as liver fibrosis may lead to end-stage liver
cirrhosis and liver cancer [2]. Excessive consumptions of
alcohol and viral infections are themost common risk factors
for liver diseases in developed countries, while environ-
mental pollution, hepatic viruses, parasitic infections, and
chemotherapeutics are the main factors known to cause he-
patic damage in developing countries [3].
In spite of medical advances, conventional medicinal
approaches have undesirable adverse eﬀects, lack eﬃciency,
and are costly, especially for patients in developing countries
[4]. Elimination of risk factors and alleviation of liver fibrosis
are the most common approaches to prevent liver deteriora-
tion [5]. Therefore, there is an urgent need for safe alternative
therapeutics to treat liver pathology. Many natural products
are being targeted for liver disease prevention and/or treat-
ment [1]. In recent years, mushrooms have been investigated
for their potential for treating liver diseases [2, 6].
A mushroom is “a macrofungus with a distinctive fruit-
ing body, which can be either hypogeous or epigeous, large
enough to be seen with the naked eye and to be picked by
hand” [7]. Mushrooms have been traditionally valued for
their nutritional and pharmaceutical properties [8]. Mush-
rooms have been a major component of Chinese folk medi-
cine since ancient times and it is only quite recently that sci-
entists have begun investigating their bioactive compounds
and health modulating mechanisms [9]. In Chinese tradi-
tional medicine, mushroom extracts are mixed with herbs
in diﬀerent combinations to treat various medical disorders
[10].
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Mushrooms have a huge potential in drug and nutraceu-
tical development. They possess a wide range of pharmac-
ological activities and thus can be considered a functional
food. A large number of compounds with antimicrobi-
al, antiviral, antioxidant, antitumor, antiallergic, anti-in-
flammatory, antiatherogenic, immunomodulating, hypogly-
cemic, hepatoprotective, and central activities has been char-
acterized and isolated from mushrooms [9]. The dried fruit-
ing bodies of mushrooms and extracts of mycelia grown
in solid substrate and liquid fermentations are marketed as
supplements in the form of powders, capsules, or tablets [11].
Panus giganteus (Berk.) Corner was introduced by mush-
room growers and the Department of Agriculture, Malaysia,
in 2003. It was previously known as “cendawan perut lembu”
(cow’s stomach mushroom) and has been renamed as low-
land shiitake or “cendawan seri pagi” (morning glory mush-
room). Panus giganteus is a known edible mushroom and
widely consumed by the indigenous communities in Ma-
laysia. Early studies have shown that P. giganteus can be
easily cultivated in Malaysia. Large-scale cultivation of this
mushroom looks promising with a good market price in
Malaysia due to its delicate flavour. The cultivation of P.
giganteus though relatively new in Malaysia is popular in
China [12].
There is, however, a paucity of scientific data pertaining
to its medicinal and nutritional benefits when compared
to other edible mushrooms such as Ganoderma lucidum
[13] and Pleurotus sajor-caju [14]. The aim of the present
study was to evaluate the in vivo hepatoprotective eﬀects of
P. giganteus fruiting bodies against TAA-induced liver injury.
2. Materials and Methods
2.1. Mushroom Samples and Chemicals. Panus giganteus
fruiting bodies collected from NAS Agrofarm Sdn. Bhd. were
freeze dried (Christ freeze dryer Alpha 1-4 LD plus) and
ground to a powder in a Waring commercial blender. The
powder was thenmixed with distilled water and administered
orally to the experimental rats. In the present study, freeze-
dried fruiting bodies were administered to the experimental
rats to simulate human consumption of the P. giganteus fruit-
ing bodies.
Silymarin was purchased from International Laboratory
USA. According to Wills and Asha, silymarin as a standard
drug has demonstrated excellent liver protection activity at a
dose of 50mg/kg [15]. Thus, a dose of 50mg/kg was chosen
in this experiment. Thioacetamide (TAA) and other chem-
icals were of analytical grade and purchased from Sigma-
Aldrich or Fisher Scientific (M) Sdn. Bhd. Thioacetamide
was dissolved in sterile distilled water at a concentration
of 200mg/kg body weight and injected intraperitoneally to
the experimental rats [3]. The 8-hydroxy-2-deoxy Guanosine
EIA detection kit was a product from Cayman Chemical
(589320).
2.2. Experimental Rats. The experimental protocol was ap-
proved by the Animal Ethics Committee (ethic number:
Table 1: The various treatments to assess the hepatoprotective ef-
fects of P. giganteus during the two-month study.
No. Group Treatment
1
Control
(distilled water)
Sterile dH2O (5mL/kg, po) daily;
sterile dH2O (5mL/kg, i.p) thrice weekly
2
Control
(P. giganteus)
Panus giganteus (0.5 g/kg, po) daily;
sterile dH2O (5mL/kg, i.p) thrice weekly
3
TAA control
(200mg/kg)
Sterile dH2O (5mL/kg, po) daily;
TAA (200mg/kg, i.p) thrice weekly
4
Silymarin
(50mg/kg) + TAA
Silymarin (50mg/kg, po) daily;
TAA (200mg/kg, i.p) thrice weekly
5
Panus giganteus
(0.5 g/kg) + TAA
Panus giganteus (0.5 g/kg, po) daily;
TAA (200mg/kg, i.p) thrice weekly
6
Panus giganteus
(1 g/kg) + TAA
Panus giganteus (1 g/kg, po) daily;
TAA (200mg/kg, i.p) thrice weekly
po: oral feeding; i.p: intraperitoneal injection.
PM/28/08/2009/MAA (R)). All experimental rats were han-
dled appropriately in accordance with the criteria prepared
by the National Academy of Sciences Malaysia as outlined
in the “Guide for the care and use of laboratory animals”.
The Sprague Dawley rats of both sexes (200–250 g) were
purchased from the Animal House Unit, Faculty ofMedicine,
University of Malaya, Malaysia. They were acclimated for
three days prior to the experiment and were housed in
specially prepared cages at 25 ± 3◦C, 12 hours light-dark
cycle with relative humidity of 50–60%. All the rats had free
access to the standard diet and water ad libitum.
2.3. Acute Toxicity Study. Male and female Sprague Dawley
rats were each divided into three diﬀerent groups (n = 6)
and assigned either as vehicle {sterile distilled water, 5mL/kg,
oral feeding (po)}, low-dose P. giganteus (2 g/kg, po), and
high-dose P. giganteus (5 g/kg, po). The rats were not fed
overnight prior to the treatments. After treatments, the
rats were observed for toxicity symptoms and behavioural
changes for a period of 48 hours. The observations continued
up to day 14. Then, the rats were sacrificed after fasting
overnight on the 15th day. Livers and kidneys were excised
for gross necropsy and histopathological examination.
2.4. Hepatoprotective Eﬀects of Freeze-Dried Fruiting Bodies
Against TAA-Induced Liver Injury. Male and female Sprague
Dawley rats were divided into six groups (n = 6) and sub-
jected to various treatments for two months as depicted in
Table 1.
The animals were weighed once a week and were ob-
served for behavioural changes. At the end of the two-month
treatment period, all rats were sacrificed under diethyl
ether anesthesia after fasting overnight. Blood samples were
collected and serum was isolated for biochemical assays. The
livers were excised, rinsed in saline, blotted with filter paper,
and weighed. Gross necropsy was performed to evaluate
any abnormalities of the livers. Subsequently, the livers were
processed for histopathological examination [3].
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Table 2: Eﬀects of diﬀerent treatments on body and liver weights of experimental rats.
Group Body weight, BW (g) Liver weight, LW (g) LW/BW (%)
Control (distilled water) 384.50 ± 36.57b 9.69 ± 0.99ab 2.51 ± 0.04a
Control (P. giganteus) 370.33 ± 41.87ab 9.92 ± 1.10ab 2.70 ± 0.08a
TAA control (200mg/kg) 296.17 ± 18.47ab 12.85 ± 0.87b 4.36 ± 0.20c
Silymarin (50mg/kg) + TAA 265.00 ± 15.53a 8.55 ± 0.75a 3.21 ± 0.13b
Panus giganteus (0.5 g/kg) + TAA 283.33 ± 17.06ab 10.28 ± 0.54ab 3.64 ± 0.09b
Panus giganteus (1 g/kg) + TAA 306.33 ± 18.79ab 10.55 ± 0.63ab 3.45 ± 0.09b
Two-month treatment; food and water ad libitum. All values are expressed as mean ± S.E.M.; n = 6. Means with diﬀerent letters (a–c) were significantly
diﬀerent at the level P < 0.05.
2.5. Eﬀects of Diﬀerent Treatments on Biochemical Parameters
Related to Hepatoprotection. The blood samples were cen-
trifuged at 3500 rpm (1534×g) for 10 minutes (Jouan C312
centrifuge). The resulting serum was then collected and sent
to the Clinical Diagnostic Laboratory, University of Malaya
Medical Centre to determine the liver biomarkers such as
alkaline phosphatase (ALP), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), gamma-glutamyl trans-
ferase (GGT), bilirubin, total protein (TP), and albumin
by using standard spectrophotometric measurements. Fur-
ther, the determination of serum malondialdehyde (MDA)
content was performed by thiobarbituric acid-reacting sub-
stances (TBARS) method as described by Daker et al. with
minor modifications [16]. The results were calculated as
1,1,3,3-tetraethoxypropane (TEP) equivalents based on the
TEP standard calibration. Oxidative damage of DNA was
determined bymeasuring the levels of free 8-OH-dG in urine
according to the protocol of the manufacturer (Cayman
Chemical-589320). Urine was collected 24 hours before the
rats were sacrificed and kept in −80◦C freezer.
2.6. Histopathological Examination. Livers and kidneys from
the experimental rats were sliced and fixed immediately
after collection in 10% (v/v) formalin for at least 24 hours.
The organs were then processed in an automated tissue-
processing machine, embedded in paraﬃn, and cut into
5 µm sections. Subsequently, the sections were stained with
hematoxylin-eosin and observed under a microscope to eval-
uate histopathological changes.
2.7. Statistical Analysis. All results were expressed as mean ±
S.E.M. (n = 6). The data was analysed by one-way analysis of
variance (ANOVA) followed by Tukey’s multiple comparison
test. The level of significance was set at P < 0.05.
3. Results
3.1. Acute Toxicity Study. There was no morbidity and mor-
tality observed throughout the study. Panus giganteuswas not
toxic to the experimental rats up to the high dose of 5 g/kg.
3.2. Eﬀects of Diﬀerent Treatments on Body and Liver Weights
of Experimental Rats. The body and liver weights of the rats
after two months of diﬀerent treatments are shown in
Table 2. Overall, there were no significant diﬀerences in body
weight and liver weight between the rats in the diﬀerent
experimental groups. However, the rats treated with TAA
exhibited significantly (P < 0.05) higher liver body weight
ratios when compared to rats in control groups. The highest
liver body weight ratio observed in TAA control rats was
73.71% higher than the ratio in the control rats (distilled
water). Administration of P. giganteus (0.5 g/kg and 1 g/kg)
lowered the liver body weight ratio and this was compa-
rable to the eﬀects observed in silymarin-administered rats
(Table 2).
3.3. Eﬀects of Diﬀerent Treatments on Biochemical Parameters
Related to Hepatoprotection. The changes in serum liver bio-
markers are shown in Table 3. Rats in both control groups
had similar biochemical indices. Particularly, TAA control
rats exhibited the highest levels of ALP, ALT, AST, GGT, and
bilirubin but lowest total protein and albumin content when
compared to rats in other experimental groups. The serum
ALP, ALT, AST, GGT, and bilirubin were 210.91%, 40.49%,
21.14%, 153.40%, and 198.75% higher when compared to
serum levels in rats in the control group (distilled water).
Total protein and albumin content dropped by 7.93% and
17.26%, respectively, when compared to rats in the control
group (distilled water).
When a low dose of P. giganteus (0.5 g/kg) was adminis-
tered, the levels of ALP, ALT, GGT, and bilirubin were signif-
icantly (P < 0.05) reduced while total protein and albumin
content were significantly (P < 0.05) elevated. There were no
significant diﬀerences in all the serum liver biomarkers of rats
in the low-dose (0.5 g/kg) or high-dose (1 g/kg) treatment
groups (Table 3). The rats administered with P. giganteus had
significantly (P < 0.05) lower levels of ALP but comparable
levels of ALT, AST, GGT, bilirubin, total protein, and albumin
when compared to the rats administered with silymarin.
The levels of oxidative stress parameters (serum MDA
and urinary 8-OH-dG) of the experimental rats are given in
Figures 1 and 2. In general, rats in both control groups dis-
played similar levels of serum MDA and urinary 8-OH-dG.
Notably, TAA control rats had significantly (P < 0.05) higher
levels of MDA when compared to rats in other experimental
groups and significantly (P < 0.05) higher urinary 8-OH-dG
content when compared to rats in control groups and rats
administered with a high dose of P. giganteus. Panus giganteus
treatments reduced the serum MDA and urinary 8-OH-dG
content. In addition, there were no significant diﬀerences
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Figure 1: Comparison of serum MDA (nM of TEP equivalents)
levels of experimental rats in diﬀerent groups after two-month
treatment. All values are expressed as mean ± S.E.M.; n = 6. Means
with diﬀerent letters (a-b) were significantly diﬀerent at the level
P < 0.05. MDA: malondialdehyde.
in oxidative stress biomarkers between the rats administered
with P. giganteus and those given silymarin.
3.4. Gross Necropsy and Histopathological Examination. In
the acute toxicity assay, gross necropsy and histopathological
examination were performed on the livers and kidneys of
the rats. There were no abnormalities or irregularities in
the organs of all three experimental groups. The histopatho-
logical examination did not show any significant diﬀerences
in cellular structures of livers and kidneys between the rats
in the P. giganteus administered groups and those in the
control group. Figure 3 illustrates the histological sections
of livers (1A, 1B, and 1C) and kidneys (2A, 2B, and 2C) in
the acute toxicity study. Liver sections of rats administered
with P. giganteus had a regular hepatic architecture. Distinct
hepatic cells and well-preserved cytoplasm were observed.
The kidney tissues retained the tubular structure and the
cellular outlines were similar to rats in the control group.
In the hepatoprotection experiment, gross necropsy and
histopathological examination of liver tissues were correlated
to the serum biochemical indices. Gross images of the livers
are presented in Figure 4 (Al–F1) while Figure 4 (A2–F2)
displays the histological sections of the livers. The livers
of rats in both control groups had smooth surfaces with-
out any irregularities (Figure 4: A1 and B1). Histological
observations of the liver sections showed regular cellular
architecture with distinct hepatic cells, sinusoidal spaces, and
a central vein. The hepatic cells displayed prominent nuclei
and uniform cytoplasm (Figure 4: A2 and B2).
In contrast, the livers of the rats in the TAA control group
were enlarged with obvious inferior margins and contained
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Figure 2: Comparison of urinary 8-OH-dG (pg/mL) levels of ex-
perimental rats in the diﬀerent groups after two-month treatment.
All values are expressed as mean ± S.E.M.; n = 6. Means with
diﬀerent letters (a-b) were significantly diﬀerent at the level P <
0.05. 8-OH-dG: 8-hydroxydeoxyguanosine.
many micro and macronodules (Figure 4: C1). The liver
sections of the TAA control rats revealed extensive damage,
characterized by severe necrosis, fatty degeneration, sinu-
soidal dilatation and congestion, centrilobular necrosis, pro-
liferation of bile duct, presence of collagen bundles sur-
rounding the lobules, which lead to thick fibrotic septae that
disrupts the cellular architecture (Figure 4: C2). However,
liver recovery was observed in rats administered with sily-
marin with liver condition and hepatic architecture similar
to control groups (Figure 4: D1 and D2).
The liver enlargement and nodules were reduced in
rats which were administered with low dose of P. giganteus
(0.5 g/kg, Figure 4: E1). The histology of the liver sections
in rats administered with low dose of P. giganteus showed
significant improvement with less damage of liver tissue
indicated by reduced level of necrosis, narrow fibrotic septae,
remarkable increase in bile ductules, fat storing cells, and
Kupﬀer cells (Figure 4: E2). Excellent liver recovery was
indicated in rats administered with high doses of P. giganteus
(1 g/kg) with liver morphology comparable to the control
rats (Figure 4: F1). There was minimal disruption of the
hepatic cellular structure; very minor fibrotic septae and a
low degree of lymphocyte infiltration (Figure 4: F2).
4. Discussion
Panus giganteus did not have any adverse eﬀects on exper-
imental rats up to the high dose of 5 g/kg (equivalent to
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(1A) (2A)
(1B) (2B)
(1C) (2C)
Figure 3: The photomicrography of liver and kidney sections of rats administered with P. giganteus at doses of 2 g/kg, 5 g/kg and distilled
water. (1A and 2A) liver and kidney sections of control rat; (1B and 2B) liver and kidney sections of rat administered with low dose of P.
giganteus (2 g/kg); (1C and 2C) liver and kidney sections of rat administered with high dose of P. giganteus (5 g/kg). (H&E stain, original
magnification: 20x).
28.57 g of fresh mushrooms) tested. There were neither mor-
tality nor toxicity symptoms observed throughout the exper-
iment. Gross necropsy and histopathological examination of
the livers and kidneys further confirmed the nontoxicity of P.
giganteus.
In the hepatoprotection experiment, although there were
no significant changes in body and liver weights in the
diﬀerent experimental groups, higher liver body weight
ratios had been observed in TAA-treated rats compared to
rats in control groups. Measurement of liver body weight
ratio is a more accurate approach to determine the changes
in liver size compared to the measurement of liver weight
alone as the liver weight largely depends on the size of the
rat. The enlargement of livers in TAA treated rats signified
hepatic lesions and liver injury associated with the toxico-
logical eﬀects of TAA. However, the liver enlargement was
significantly (P < 0.05) reduced in rats administered with P.
giganteus and this was comparable to the eﬀects of silymarin.
Serum liver biomarkers (ALP, ALT, AST, GGT, bilirubin,
total protein, and albumin) are important criteria for the
evaluation of liver toxicity. The amounts of enzymes that
leak into the blood stream indicate the severity of hepatic
damage [17]. Additionally, the decreased level of albumin
or hypoalbuminemia and total protein in TAA control rats
could be due to malnutrition related to liver cirrhosis. In the
present study, the rats intoxicated with thioacetamide (TAA)
experienced hepatic injury evidenced by significant changes
(P < 0.05) in serum liver biomarkers when compared to
normal control rats. However, P. giganteus exhibited hepato-
protective eﬀects to restore the altered serum liver parameters
comparable to the eﬀects of silymarin. This was further con-
firmed by gross necropsy and histopathological examination.
Generations of reactive oxygen species (ROS), mito-
chondrial dysfunction, and antioxidant insuﬃciency have
been reported to advance the development of liver cirrhosis
[18]. In order to evaluate the eﬀects of TAA on oxidative
stress in rats, we examined the oxidative stress parameters
such as serum MDA and urinary 8-OH-dG content which
reflect oxidative damage to lipids and DNA, respectively.
Malondialdehyde (MDA) has been quantified since the 1960s
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(A1)
(A2)
(B1)
(B2)
(C1)
(C2)
(D1)
(D2)
(E1)
(E2)
(F1)
(F2)
Figure 4: The gross liver morphology (A1–F1) and photomicrography of liver sections (A2-F2) of rats treated with TAA and administered
with P. giganteus at doses of 0.5 g/kg, 1 g/kg, and distilled water. The rats in TAA, silymarin, and P. giganteus treatment groups were injected
with TAA via the intraperitoneal-route thrice a week. (A1 and A2) control rat (distilled water); (B1 and B2) control rat (P. giganteus); (C1
and C2) TAA control rat: gross image shows many micro- and macronodules in the liver (arrow), while light micrograph shows thick fibrotic
septae with proliferation of bile duct (arrow); (D1 and D2) Rat administered with silymarin. (E1 and E2) rat administered with low dose of
P. giganteus (0.5 g/kg): micronodules were noted in the gross image (arrow), light micrograph shows narrow fibrotic septae (arrow); (F1 and
F2) rat administered with high dose of P. giganteus (1 g/kg): very minor fibrotic septae was observed in the light micrograph (arrow). (Figure
A2–F2: H&E stain, original magnification: 20x).
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and is still widely used as a biomarker to detect lipid perox-
idation due to the low cost and simplicity of the application
[19]. Numerous reports have revealed that the measurement
of TBARS is useful to study the pathological states in
tissues of animal origin [6, 20]. Earlier studies suggested
that hepatotoxins including TAA, induced liver damage by
forming free radicals, which then react with cellular lipids to
promote lipid peroxidation [21]. The higher MDA level in
TAA control rats observed in the present study also supports
this suggestion.
The free 8-OH-dG assay was used for the evaluation of
DNA damage caused by oxidative stress. The free radicals
may damage nucleic acids, cellular lipids, and proteins at
high concentrations [22]. Although oxidative damage of
DNA results in a large number of diﬀerent biochemical
eﬀects, the main focus has been on nucleobase alterations
especially the lesion of 8-OH-dG as it is produced in vivo and
can be estimated in cells after the DNA has been attacked
by hydroxyl radicals [23]. Particularly, the urinary 8-OH-
dG content has been most commonly used due to the
simplicity and noninvasiveness of the method [24]. Kasai
and Nishimura were the first to report the use of 8-OH-
dG to analyse DNA damage caused by hydroxylation at the
C8 position of the nucleoside guanosine [25]. Since then,
numerous studies have been carried out and improvements
have been made to the methods for the quantitation of 8-
OH-dG in urine and plasma [26].
Our results indicate that TAA control rats experienced a
higher degree of oxidative DNA damage than rats in the other
experimental groups. The lower levels of serum MDA and
urinary 8-OH-dG in rats administered with P. giganteus sug-
gest that P. giganteus may possess bioactive compounds that
could prevent the oxidative stress induced by TAA and thus
alleviate the degree of liver injury. Furthermore, as there were
no remarkable diﬀerences between the high dose (1 g/kg,
equivalent to 5.72 g of fresh mushrooms) and the low dose
(0.5 g/kg, equivalent to 2.86 g of fresh mushrooms) treat-
ments with regard to their serum biochemical indices and
histopathological evidences, it is evident that the low dose
of P. giganteus had protective eﬀects against TAA-induced
liver deterioration. Panus giganteus may be incorporated into
the diet of patients with liver disease as the present study
showed that it may reduce the severity of liver lesions, while
exhibiting no toxic eﬀects to rats in animal experiments.
Silymarin was used as a positive control because sily-
marin is a standard drug exhibiting excellent liver protection
activity [3, 15]. Hepatotoxic agents such as acetaminophen
[27], carbon tetrachloride [28], galactosamine [29], and
thioacetamide (TAA) [3] have been used to induce experi-
mental liver damage in both in vivo and in vitro studymodels.
These hepatotoxic agents induce liver damage by reacting
with basic cellular components [30]. Thioacetamide (TAA)
as a thiono-sulfur-containing compound has been widely
used as a fungicide, organic solvent, accelerator in the rubber
vulcanization, and as motor oil stabilizer [31]. Fitzhugh
and Nelson were the first to report TAA as a hepatotoxic
agent [32]. Thioacetamide binds covalently to the cellular
components and subsequently induces oxidative stress [33,
34]. Biochemically, it is metabolized by the microsomal FAD
monoxygenase (FADM) system to form reactive metabolites
such as thioacetamide sulfoxide and thioacetamide-S,S-
dioxide which then contribute to the toxicity eﬀects of TAA
[35]. Long-term exposure to TAA may lead to hyperplastic
liver nodules, liver cell adenomas, and hepatocarcinomas
[36].
According to Pe´rez et al. [37], metabolic and histological
changes in cirrhotic models induced by TAA closely resemble
those in human liver cirrhosis. Thioacetamide- (TAA-)
induced liver cirrhosis in rats served as a good model as
it reflects major human physiological changes. Moreover,
the use of TAA is more appropriate in such experiments
due to its high specificity to the liver, regiospecificity to the
perivenous area, and having a large window of time between
its hepatocytes damaging eﬀects and liver failure [38].
In the present study, the mushroom was administered at
doses of 0.5 g/kg (low dose) and 1 g/kg (high dose) as pre-
vious related studies indicated that these doses would be
eﬀective in preventing liver injury. Dai et al. showed that
oral administration of Antrodia camphorata fruiting bodies
in doses of 0.5 g/kg and 1 g/kg provided protection against
ethanol-induced acute liver damage in Sprague-Dawley rats
[39]. Lu et al. suggested the remarkable preventive eﬀects
of 0.5 g/kg and 1 g/kg Antrodia camphorata mycelia in
submerged culture against ethanol-induced hepatic toxicity
in Sprague-Dawley rats [40]. In addition, other mushroom
species including Ganoderma lucidum [6] and Pleurotus
ostreatus [20] exhibited hepatoprotective eﬀects using rats as
experimental model.
5. Conclusions
In conclusion, the acute toxicity study showed that P. gigan-
teus was not toxic to the experimental rats up to an oral dose
of 5 g/kg body weight. Furthermore, P. giganteus exhibited
significant hepatoprotective eﬀects against TAA-induced
liver injury in rats even at a low dose of 0.5 g/kg and was
comparable to the eﬀects of silymarin, a standard drug used
to treat liver diseases. The hepatoprotective eﬀects of P. gigan-
teus were associated with its ability to reduce oxidative stress.
However, further investigation is required to identify the
bioactive compounds responsible for the hepatoprotective
eﬀects and to formulate functional foods for the reduction
of liver injury severity.
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